Refeyn

Refeyn continues participation in NIIMBL consortium tackling AAV purification

Refeyn will continue its role in a project that has received additional funding through the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), focused on intelligent optimization of adeno-associated virus […] The post Refeyn continues participation in NIIMBL consortium…

Refeyn welcomes Paul C. Collins to Scientific Advisory Board

Paul C. Collins Director of Research at Purdue University Refeyn is pleased to announce that Paul C. Collins has joined its Scientific Advisory Board (SAB). Paul brings a wealth of experience spanning synthetic small molecules, […] The post Refeyn welcomes Paul C. Collins to Scientific Advisory…

Bio‑Techne and Refeyn close critical gap in bispecific antibody and biosimilar characterization

New integrated workflow combines icIEF fractionation and mass photometry  Enables simultaneous assessment of charge and size variants at single molecule resolution  Four-hour workflow reduces development risk and accelerates biosimilar manufacturing  MINNEAPOLIS and OXFORD, UK — […] The post…

Refeyn launches MyMassMP instrument to simplify sample quality assessment for structural biology

The MyMass™ mass photometer enables researchers to quickly verify sample quality before proceeding to cryo-EM, native MS, BLI, SPR and other demanding experimental workflows. Compact, all-in-one mass photometer helps researchers verify […] The post Refeyn launches MyMassMP instrument to simplify…

Leading CROs and CDMOs turn to mass photometry for rapid protein, mRNA and viral vector analytics

As CROs and CDMOs expand their role in biopharma development and manufacturing, fast, accurate bioanalytic technologies remain critical to biotherapeutic affordability Refeyn’s Samux™ benchtop mass photometer enables rapid analysis of adeno-associated virus (AAV) samples. […] The post Leading CROs…

Comparing analytical approaches for AAV characterization (2026)

AAV sample characterization is a critical step in research, development and manufacturing processes of gene therapies involving these viral vectors (Figure 1). There are several analytical approaches available to assess critical quality attributes (CQAs) for AAV samples, such as capsid content…